Artículo

Great achievements and new landscapes in medical cancer therapy

Gandía, Daniel ; Suárez, Cecilia Ana Icon

Otros responsables

Fecha

2019

Editorial

The Society of Adaptive Science in Taiwan

Revista

Adaptive Medicine

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

2076-944X

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Chemotherapy rapidly proved its worth in different clinical cancer settings, begining with hematologic malignancies. Many pediatric and young adult tumors achieved complete remission with chemotherapy, but its use as concomitant, adjuvant and/or neoadjuvant treatment also resulted in beneficial results. The new milenium developed new techniques in molecular drug design creating novel drugs specially directed to specific cell targets, which was a solution for some traditionally chemoresistant tumors. César Milstein begun a new road with the discovery of the monoclonal antibodies, opening the landscape of the immuno-oncology that lead to present check-point-inhibitors. In the last decades, mathematical oncology and the “omics” sciences, also came to help as complementary tools for the management of this extremely complex disease in the context of a personalized medicine. Indeed, the possibility of introducing information derived from these sciences into hybrid and/or multiscalar mathematical models are nowadays the approaches most interesting and promising; with good perspectives in the diagnosis, prognosis, treatment design and follow-up of different kinds of tumors. Although at present many tumor types can be completely cured, other ones are much more difficult to eradicate, and they would be better considered as chronic diseases. In this context, some new important concepts emerge in the metronomics field, as keeping a stable tumor burden, a more benign tumor grade and a good quality of life. This minireview addreses all these mentioned issues.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa